Cancer cachexia is an important cause of death in cancer patients (Warren, 1932) , and in addition patients with cachexia display a reduced response to chemotherapy (van Eys, 1982) . Cachexia is charaterised by progressive weight loss, and catabolism of host body compartments, particularly muscle and adipose tissue, is observed. It has been suggested (Studley, 1936 ) that 30% loss of body weight is invariably fatal, so attempts have been made to counter the weight loss in cancer patients by administering total parenteral nutrition (TPN). However, clinical studies giving extra calories via TPN have failed to alter the weight loss, and in at least two of the randomised TPN trials, a decreased survival was seen in the TPN treatment arm (Chlebowski, 1985) . Since weight loss is one of the most common adverse systemic effects of malignancy occurring early in the course of the disease (De Wys, 1985) , an understanding of the mechanism of cachexia could obviously benefit a large number of patients.
In addition to possibly increasing the quality of life and extending the length of survival of cancer patients, an understanding of the systemic effects of the tumour may provide a locus for therapeutic intervention in the treatment of solid tumours, if the products of catabolism of host tissues are important in the maintenance of tumour growth.
The principal products released from the degradative activity on adipose tissue and muscle will be free fatty acids (FFA) and amino acids. Tumours have a poor capacity to synthesise their own lipids despite the fact that they are important components of cellular membranes and also play an important role as intracellular mediators such as eicosanoids, diacylglycerol and inositol phospholipids. Nutritional conditions which lead to catabolism of host adipose tissue, such as an acute fast (Sauer & Dauchy, 1987a) and acute streptozotocin-induced diabetes (Sauer & Dauchy, 1987b) , result in a stimulation of tumour growth, suggesting that the products from host fat stores may be limiting for tumour growth in vivo. It is most likely that the mitogenic effect results from the release of polyunsaturated fatty acids such as linoleic or arachidonic acids. Phospholipids containing such polyunsaturated fatty acids, esterfied to the sn-2 position of the glycerol moiety, have been shown to stimulate cell growth (Imagawa et al., 1989) , possibly by inhibiting a guanosine triphosphatase activating protein, which in turn inactivates the ras protein (Tsai et al., 1989) . This suggests that these lipids can potentiate ras functions.
In addition amino acid requirements are altered in the tumour-bearing state. Host leucine requirements have been shown to be increased in the presence of a rapidly growing murine tumour (Lazo, 1981) , and depletion of the nonessential amino acid asparagine by the enzyme asparaginase has led to the treatment of acute lymphocytic leukaemia in man (Holland & Ohnuma, 1979) . Some malignant cells have specific requirements for L-cysteine (Uren & Lazarus, 1979) , methionine (Tisdale, 1980) , tyrosine and phenylalanine (Demetrakopoulos & Brennan, 1982) , serine and threonine (Pizer & Reagan, 1972 of amino acids. Disposal of the remaining amino acids has been postulated to explain the abnormal gluconeogenesis seen in cancer patients (Stein, 1978) . In view of the extra requirements of the tumour for specific nutrients, it is not surprising that catabolism of host tissues is so common in cancer.
Model systems of cachexia
In order to understand the underlying mechanisms of cancer cachexia it is important that an appropriate model system is used. Cachexia can appear in patients with tumours which are less than 0.01% of the total body weight (Nathanson & Hall, 1974) , and the total tumour mass in the majority of cancer patients rarely exceeds 0.5 Kg (Costa, 1977) . Cachexia is also not related to the growth rate or anatomical site of involvement of the tumour. Few of the experimental models which have been used to study the mechanisms of cachexia fulfill the criteria that cachexia should be an early effect of the tumour, and be present with a small tumour burden. Instead cachexia is usually studied in rapidly growing rodent tumours, and appears as a late effect, usually just before death, when the tumour mass has reached a high proportion of the total weight of the animal. Usually these models attribute the cachexia to a drop in food intake and competition of the tumour with the host for essential nutrients (Garattini et al., 1980) . The few models which do fulfill the criteria of an early effect and a small tumour mass, observe weight loss without a detectable loss of appetite (Strain et al., 1980; Bibby et al., 1987; Tanaka et al., 1990) .
In view of the small tumour mass producing weight loss in such models, it is unlikely that a simple competition between host and tumour is responsible. Indeed, if the tumour-bearing state is compared with pregnancy, the foetus grows at a much faster rate, and is a higher proportion of the total body weight than most tumours. However, in this case the mother actually increases weight. It is also unlikely that weight loss arises solely from an enhanced gluconeogenesis to supply the glucose requirements of the tumour (Gold, 1974) , although futile cycles such as the Cori cycle and an increased lipogenesis from glucose probably contribute to the increased metabolic demands in the tumour-bearing state.
Mechanism of cachexia
We have considered the hypothesis that wasting occurs through direct catabolism of host components by tumour products. There is a considerable amount of data in the literature to support such a hypothesis, particularly with regard to lipid mobilisation. Thus nonviable preparations of Krebs-2 carcinoma cells, when injected into male Swiss mice, were able to produce a decrease in carcass fat of a level comparable with that obtained by viable cell preparations (Costa & Holland, 1966) . Using '4CO2 production from 14C fatty acid labelled adipose tissue as a measure of lipolysis Kitada et al. (1980) were able to show that extracts of a thymic lymphoma, as well as serum from mice bearing such a tumour, and culture medium from the cell line growing in vitro, were able to mobilise fatty acids from the hosts' adipose tissue. The fact that activity was obtained with the in vitro cell line suggested that the lipid mobilising factor was tumour rather than host derived.
Carcass lipid depletion in tumour-bearing nude mice has been shown to be a function of tumour type rather than tumour burden (Hollander et al., 1986) (Beck & Tisdale, 1987 Kitada et al. (1981) suggested that the lipid mobilising factor produced by thymic lymphoma cells was a heat stable protein of molecular weight of about 5 kDa, while later studies reported the active material to be of much higher molecular weight, and to be formed by aggregation of the low molecular weight material (Kitada et al., 1982) . A somewhat similar acidic (pI4.7) lipid mobilising factor of molecular weight 65 to 74 kDa (toxohormone L), has been found in the pleural fluid from patients with malignant lymphoma and the ascites fluids of patients with ovarian carcinoma or hepatoma (Masuno et al., 1981) .
Further characterisation of either of these materials has not been reported, although proteolysis of toxohormone L to low molecular weight materials did not destroy lipolytic activity, suggesting some similarity to the low molecular weight material investigated by Kitada et al. (1981) .
Most recent studies have concentrated on a macrophage product, cachectin, regarded as the mediator of cachexia in animals infected with Trypanosomes (Rouzer & Cerami, 1980) and later shown to be homologous to tumour necrosis factor (TNF) (Beutler et al., 1985a) . Several studies have demonstrated the ability of TNF to induce weight loss in experimental animals (Oliff et al., 1987) . Weight loss produced by TNF is typified by a marked anorexia, and the decrease in food and water intake is directly proportional to the decrease in body weight . However, anti-TNF antisera has been shown to delay, but not fully protect against the decrease in food intake in sarcomabearing mice (Sherry et al., 1989) , suggesting that other factors in addition to TNF may be responsible for the anorexia in tumour-bearing animals. It has been suggested that TNF produces an effect on lipid metabolism through an inhibition of the enzyme lipoprotein lipase (Beutler et al., 1985b) , and thus depletion of host lipids would be mediated through a different mechanism from the action of the direct catabolic factors mentioned above. Inhibition of lipoprotein lipase by TNF results in hypertriglyceridemia. However, hypertriglyceridemia persists even with tachyphylaxis to the anorectic effects of TNF, suggesting that the two are not inevitably linked (Grunfeld et al., 1989) .
Although there is a considerable amount of literature on the biological effects of TNF, the role in cancer cachexia is not clear. Attempts to reverse the cachexia in tumour-bearing animals with anti-TNF antibodies have produced equivocal results (Sherry et al., 1989) . Unfortunately, both models used by these workers had a higher tumour burden, and measurements were made at the time of death. In sarcoma-bearing mice anti-TNF antibodies apparently reduced the loss of both carcass and fat mass on the day of death. However, two factors were not taken into consideration. Firstly, animals given anti-TNF antibodies were eating more than control animals when measurements were made, and secondly treatment reduced tumour size, which would also be expected to reduce catabolism of host tissues. In a second study with Lewis lung adenocarcinoma-bearing mice, anti-TNF antibodies diminished the degree of carcass lipid depletion and prevented hypertriglyceridemia. However, as indicated above (Grunfeld et al., 1989 ) hypertriglyceridemia may not be linked to the anorexia/cachexia syndrome produced by TNF. In neither model did anti-TNF antibodies affect the development of anaemia, hypoalbuminaemia or the increase in serum myeloid P concentration seen with increasing tumour burden.
These results suggest that if TNF is involved in the weight loss in some experimental models then other factors must also be present to explain all of the features of cachexia.
Three lines of evidence are required to support the role of a postulated cachectic factor in the development of cachexia.
(1) There should be measurable circulatory levels of the factor and the appearance and level of the material should be correlated with the degree of the cachexia in view of the parabiotic transfer of cachexia in rats (Norton et al., 1985) . (2 . Most studies with cancer patients have also reported undetectable serum levels of TNF (Selby et al., 1987) , even in patients that had lost eight to 40% of their pre-morbid weight (Socher et al., 1988) . Two studies have, however, reported elevated serum levels of TNF, one in children with malignancy (Saarinen et al., 1990) , and another in cancer patients with active disease (Balkwell et al., 1987) . The rise in the plasma level of lipolytic activity reached a maximum when the animals had lost 16% of the body weight (Figure la) , and thereafter declined.
Occassionally animals bearing the MAC16 tumour do not develop weight loss and for these animals there is no increase in plasma lipid mobilising activity (Figure lb) . Using the same assay system the serum lipolytic activity was found to be much higher in cancer patients with weight loss than a group of patients with Alzheimer's disease and comparable Weight loss (kg) Figure 2 Relationship between serum lipolytic activity and weight loss in a group of cancer patients. The lipolytic activity is expressed as in Figure 1 . The average value for normal subjects was 0.06± 0.01 jlmoles glycerol 105 adipocytes 'ml-'.
weight loss . As for animals bearing the MAC16 tumour the serum level of lipolytic activity in cachectic cancer patients was proportional to the degree of weight loss when the total body weight loss did not exceed 20% (Figure 2) . Patients who responded to therapy showed a decrease in the plasma levels of lipid mobilising activity, which correlated with the level of response . The lipid mobilising activity was characterised by the retention by DEAE cellulose, and using this criterion it was observed that similar material was absent from normal serum. This suggests that the lipid mobilising factor is acidic in character, similar to that previously reported (Kitada et al., 1981; Masuno et al., 1981) , and is different from the natural lipolytic hormones, which are all basic in character.
Effect of cachectic factors on host body weight A number of studies have demonstrated the ability of TNF to induce weight loss in experimental animals, although some workers question the ability of TNF alone to yield a sustained cachectic effect (Mullen et al., 1990) . In all cases weight loss is accompanied by a marked anorexia, and the depression in food and water intake is probably responsible for the wasting effect. Indeed when the anorexia is counteracted with the synthetic steroid megestrol acetate the ability of TNF to induce weight loss is abolished . Megestrol acetate has been shown to produce weight gain in more than 80% of cancer patients administered this agent, with a subjective improvement of appetite occurring in most cases (Aisner et al., 1988) . Thus TNF may be responsible for the anorexia commonly encountered in cancer cachexia. However, the cachectic effect of TNF when administered parenterally is usually transient, since tachyphylaxis soon develops. In order to produce a prolonged weight loss escalating doses of TNF are required, which exceed the LD50 of the agent (Tracey et al., 1988) . Thus experimentallyinduced weight loss may be due to the toxic effect of TNF, since a similar condition is observed with the antitumour agent mitozolomide . These results suggest that other factors may be required to explain the weight loss produced by TNF-producing tumours (Oliff et al., 1987) . Treatment of animals with the lipid mobilising factor isolated from the MAC16 tumour also produces a decrease in body weight (Figure 3 ). This weight loss occurs without an alteration in food intake, and is more pronounced in tumourbearing animals than in non tumour-bearing animals. (Beck & Tisdale, 1987) . Insulin is an important anabolic hormone which has been suggested as a possible supportive measure in the total nutritional management of the cancer patient (Schein et al., 1979) . In animals bearing the MAC16 tumour daily insulin administration was shown to reduce host body weight loss, and increase both carcass fat and muscle mass, without an effect on food or water consumption (Beck & Tisdale, 1989a) . This was only achieved, however, by an increase (about 50%) in the final tumour weight. While in a rat model insulin was shown to produce a significant increase in host body weight without affecting tumour growth (Moley et al., 1985) the known growth stimulatory properties of insulin (Barnes & Sato, 1980) (Cotter et al., 1987 .
The effect occurred without an alteration in caloric consumption, and was associated with an increase in both the fat and non-fat carcass mass, and both nitrogen balance and urea excretion were restored to that in non tumour-bearing animals (Beck & Tisdale, 1989b) . Cancer patients with severe weight loss (mean 32%) also showed an increase in body weight when fed an isocaloric diet in which 70% of the calories were derived from MCT (Fearon et al., 1988 (Tisdale & Dhesi, 1990 (Tisdale & Beck, 1991 (Sharp & Hynie, 1971 (Karmali et al., 1989) .
